Pathophysiology of Osteoporosis. New Mechanistic Insights.

Laura A G Armas, Robert R. Recker

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Understanding of the pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective repair of microdamage from normal daily activities, and (4) excessive bone remodeling rates. These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation, antiresorptives, mechanical loading, and disuse have helped further knowledge of the factors affecting bone quality and the mechanisms that underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.

Original languageEnglish
Pages (from-to)475-486
Number of pages12
JournalEndocrinology and Metabolism Clinics of North America
Volume41
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Osteoporosis
Bone and Bones
Bone Remodeling
Estrogens
Pharmaceutical Preparations
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Pathophysiology of Osteoporosis. New Mechanistic Insights. / Armas, Laura A G; Recker, Robert R.

In: Endocrinology and Metabolism Clinics of North America, Vol. 41, No. 3, 09.2012, p. 475-486.

Research output: Contribution to journalReview article

@article{8869692e383a499bb2bd188a270b9e18,
title = "Pathophysiology of Osteoporosis. New Mechanistic Insights.",
abstract = "Understanding of the pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective repair of microdamage from normal daily activities, and (4) excessive bone remodeling rates. These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation, antiresorptives, mechanical loading, and disuse have helped further knowledge of the factors affecting bone quality and the mechanisms that underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.",
author = "Armas, {Laura A G} and Recker, {Robert R.}",
year = "2012",
month = "9",
doi = "10.1016/j.ecl.2012.04.006",
language = "English",
volume = "41",
pages = "475--486",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Pathophysiology of Osteoporosis. New Mechanistic Insights.

AU - Armas, Laura A G

AU - Recker, Robert R.

PY - 2012/9

Y1 - 2012/9

N2 - Understanding of the pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective repair of microdamage from normal daily activities, and (4) excessive bone remodeling rates. These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation, antiresorptives, mechanical loading, and disuse have helped further knowledge of the factors affecting bone quality and the mechanisms that underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.

AB - Understanding of the pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective repair of microdamage from normal daily activities, and (4) excessive bone remodeling rates. These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation, antiresorptives, mechanical loading, and disuse have helped further knowledge of the factors affecting bone quality and the mechanisms that underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84864819754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864819754&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2012.04.006

DO - 10.1016/j.ecl.2012.04.006

M3 - Review article

VL - 41

SP - 475

EP - 486

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 3

ER -